[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto de Investigacion Sanitaria La Fe\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":281},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,58,91,126,151,176,201,234,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100614320","impact-of-dietary-fat-and-menstrual-cycle-phases-in-type-1-diabetes-100614320",false,"NCT07278063","Impact of Dietary Fat and Menstrual Cycle Phases in Type 1 Diabetes","Effect of Gender and Meal Composition on the Postprandial Glycemic Response in People With Type 1 Diabetes: Impact of Fat Content and Menstrual Cycle Phases","DIABETEXX\u002F3","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of type 1 diabetes mellitus for more than 2 years, in treatment with AHCL (Advanced Hybrid Closed Loop) system treatment for at least 6 months.\n* Both sexes.\n* Metabolic control with HbA1c \\\u003C8%.\n* BMI between 18.5 and 29.99 (normal weight to overweight).\n* For women: regular menstrual cycles (21-35 days in length with variation between cycles of \\\u003C4 days) and no use of hormonal contraceptive treatment.\n\nExclusion Criteria:\n\n* Diagnosis of diabetic gastroparesis.\n* Presence of hypogonadism, anovulation, hyperandrogenism, hyperprolactinemia, pregnancy, or decompensated chronic diseases.\n* Use of oral medications that alter glucose metabolism.","ALL","18 Years","45 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial aims to evaluate how variations in dietary fat content and hormonal status influence postprandial glycemic response in individuals with type 1 diabetes (T1D), with a special focus on women. The main objective is to clarify the impact of both factors individually and their interaction, which could inform more personalized strategies for insulin adjustment, optimizing glycemic control, and improving patient outcomes.\n\nThe main objective is to investigate the effects of low-fat versus high-fat meals, sex, menstrual cycle phases, and their interaction on postprandial glycemic control in adults with T1D treated with advanced hybrid closed-loop (AHCL) insulin delivery systems.\n\nSpecifically, the study will:\n\n* Compare postprandial glycemic responses after standardized low and high-fat meals in men and women with T1D.\n* Assess the differences in postprandial glycemic responses between early follicular and late luteal phases in women, using standardized meals with low and high fat content.\n* Identify sex-related differences in glycemic response after equivalent meals.\n\nThis research addresses the unmet clinical need for precise, tailored postprandial insulin dosing recommendations, especially among women whose insulin sensitivity fluctuates with menstrual phases. The results may contribute to sex-specific predictive models in AHCL systems, reducing acute complications and improving overall quality of life.\n\nThis is a randomized controlled crossover trial in which each participant serves as her\u002Fhis own control. Fifty adults will be enrolled: 25 women and 25 men. Women will undergo four mixed-meal tests in random order:\n\n* low-fat given during the early follicular phase,\n* high-fat given during the early follicular phase,\n* low-fat given during the late luteal phase,\n* high-fat given during the late luteal phase. The menstrual phase will be confirmed with home-based hormonal monitoring devices that function with urine sample and use a single-use test wand (MIRA system).\n\nMen will complete two mixed-meal tests (low-fat and high-fat), in randomized order.\n\nAll meals will be standardized for carbohydrate content and matched in other macronutrients, except for fat (with a 30-40g difference), administered after an 8-hour fast. The day of the mixed meal test, AHCL systems will be switched from automatic to manual mode just before eating to standardize the prandial insulin dose and to avoid differences in insulin infusion rates in the postprandial state due to algorithm compensations. Continuous glucose monitoring (CGM) and hourly capillary glucose testing will measure the postprandial response. Additional fasting blood samples will assess metabolic, hormonal, and lipid markers. Optional gastric emptying studies may be performed to exclude confounding gastroparesis in selected patients.\n\nParticipants will be recruited from the endocrinology outpatient unit of La Fe Polytechnic University Hospital . The projected recruitment period is from December 2025 to July 2027, with mixed-meal tests and data collection occurring between January 2026 and December 2027. Women are expected to complete the protocol in 6 weeks (4 tests), while men will require about 2 weeks (2 tests).\n\nAt baseline, participants will undergo blood tests to rule out endocrine disorders and confirm sex hormone status. Women participating in the study will use the MIRA home device to monitor their hormonal levels, allowing them to accurately determine and record the phases of their menstrual cycle as part of the study protocol. During meal tests, CGM (Freestyle Libre 3) will be used uniformly among subjects.\n\nThe study dependent variables will be the following:\n\n* Postprandial glucose area under the curve - AUC\\_PG\\_5h\n* Mean glucose level - MG\n* Continuous glucose monitoring metrics - TIR, TAR, TBR\n* Postprandial glucose standard deviation - SD\n* Postprandial glucose coefficient of variation - CV\n* Mean amplitude of glycemic excursions - MAGE\n* Mean of daily differences (MODD)\n\nIndependent variables are\n\n* Type of food: Meals with either low or high fat content.\n* Sex and Hormonal status: men; women during the early follicular phase; women during the late luteal phase.\n\nIf successful, this study will inform the development of more sophisticated, individualized insulin dosing algorithms and AHCL system improvements, especially for women with T1D. Results may lead to more effective management strategies, reduced GV, lower incidence of complications, and increased quality of life. Insights may directly support the personalization of diabetes care and improve gender equity in treatment standards.",[28,29,30,31,32,33],"Type 1 Diabetes Mellitus","Glycemic Variability","Sex Characteristics","Menstrual Cycle","Dietary Fat","Postprandial Glucose",[35,36,37,38,39,40,41,42,43,44],"Type 1 diabetes","glycemic variability","advanced hybrid closed-loop systems","menstrual cycle","postprandial glucose","dietary fat","insulin sensitivity","continuous glucose monitoring","mixed-meal test","personalized insulin therapy","NOT_YET_RECRUITING","2026-03-20",{"date":48,"type":49},"2026-03-23","ACTUAL",{"date":51,"type":22},"2026-05",{"date":53,"type":22},"2028-04",{"name":55,"class":56},"Instituto de Investigacion Sanitaria La Fe","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":57},"100623857","administration-of-extracellular-vesicles-from-donor-human-milk-in-preterm-infants-100623857","NCT07402083","Administration of Extracellular Vesicles From Donor Human Milk in Preterm Infants","Administration of Extracellular Vesicles Isolated From Donor Human Milk as a Dietary Supplement for the Prevention of Necrotizing Enterocolitis in Preterm Infants","AdVEMPrem","Inclusion Criteria:\n\n* Preterm infants born at \\\u003C32 weeks gestational age\n* Age between 0 and 14 days of life at enrollment\n* At risk of developing necrotizing enterocolitis (NEC)\n* Written informed consent obtained from parent(s) or legal guardian(s)\n\nExclusion Criteria:\n\n* Major congenital anomalies or chromosomal abnormalities\n* Severe gastrointestinal malformations (e.g., gastroschisis, intestinal atresia)\n* Conditions incompatible with enteral feeding or EV supplementation\n* Participation in another interventional clinical trial","0 Days","14 Days",{"count":69,"type":22},20,"OBSERVATIONAL","The AdVEMPrem study is exploring whether tiny particles called extracellular vesicles (EVs), which are naturally found in human milk, can help protect very premature babies from serious gut problems such as necrotizing enterocolitis (NEC). NEC is a dangerous condition that affects the intestines of preterm infants and can lead to long-term health issues.\n\nHuman milk is the best nutrition for babies, but when a mother's own milk is not available, donor human milk (DHM) is used. EVs in milk carry proteins, fats, and genetic material that may support gut development, immunity, and brain growth. While laboratory studies suggest EVs are beneficial, their effects in premature babies have not yet been proven.\n\nIn this study, 20 very preterm infants (\\\u003C32 weeks of gestation) will be enrolled during their stay in the Neonatal Intensive Care Unit (NICU). All babies in the study will receive oral supplementation with EVs isolated from donor human milk. Researchers will monitor feeding tolerance, growth, intestinal health, and early development. Blood and urine samples will also be collected to study how EVs affect metabolism and stress markers.\n\nThe main goal is to see if EV supplementation is safe and well tolerated. Longer-term follow-up will explore whether EVs improve growth and neurodevelopment as the babies grow. This research could lead to new nutritional strategies to reduce NEC and improve outcomes for premature infants and their families.",[73],"Very Preterm Infants (\u003C32 Weeks of Gestation)",[75,76,77,78,79,80,81],"Preterm birth (\u003C32 weeks)","Donor human milk (DHM)","Extracellular vesicles (EVs)","Feeding tolerance","Necrotizing enterocolitis (NEC)","Neurodevelopment","Donor Human Milk Extracellular Vesicle (DHMEVs)","RECRUITING","2026-02-09",{"date":85,"type":49},"2026-02-11",{"date":87,"type":49},"2026-02-05",{"date":89,"type":22},"2029-12-31",{"name":55,"class":56},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":103,"conditions":104,"keywords":110,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":57},"100597654","transition-to-hospital-discharge-in-insulinized-patients-with-type-2-diabetes-mellitus-100597654","NCT07061301","Transition to Hospital Discharge in Insulinized Patients With Type 2 Diabetes Mellitus","Transition to Hospital Discharge in Insulinized Patients With Type 2 Diabetes Mellitus and Incorporation Into a Comprehensive Diabetes Management System","TRANHOSPIN","Inclusion Criteria:\n\n* Adults aged 18 to 70 years.\n* Hospitalized patients with a diagnosis of type 2 diabetes mellitus (T2DM), either newly diagnosed during admission or previously known but not previously treated with insulin.\n* Initiation of insulin therapy (basal, basal-plus, or basal-bolus regimen) during hospitalization, with planned continuation post-discharge.\n* Independent in basic activities of daily living.\n* Adequate cognitive and functional capacity to manage the required devices: insulin pen, glucometer, continuous glucose monitoring (CGM) sensor, and Insulclock® cap.\n\nExclusion Criteria:\n\n* Dependence in basic activities of daily living.\n* Any medical condition or functional limitation precluding the use of the CGM or the Insulclock® system.\n* Pregnancy or intention to become pregnant.\n* Diagnosis of type 1 diabetes mellitus.\n* Patients undergoing dialysis.","70 Years",{"count":101,"type":22},80,[25],"This clinical study explores whether adding technological tools during hospital discharge can help people with type 2 diabetes who are starting insulin therapy achieve better treatment adherence and blood glucose control once they return home. The discharge transition period includes both the final days of hospitalization and the first weeks to months after returning home.\n\nWhen people with type 2 diabetes are hospitalized, they sometimes need to begin insulin therapy. After discharge, managing insulin properly is essential to avoid high or low blood sugar levels. However, many patients forget or delay insulin doses, which can lead to poor control of their diabetes.\n\nThis study will compare two groups of patients. All participants will be adults with type 2 diabetes, between 18 and 70 years old, who are newly starting insulin during their hospital stay.\n\nGroup 1 (\"technological group\") will use a continuous glucose monitor (CGM) and a smart insulin pen cap called Insulclock. These tools show real-time blood glucose data and record when and how much insulin is injected. Patients and doctors can use this information to better adjust treatment. Insulclock also includes alarms to remind patients of their doses.\n\nGroup 2 (\"control group\") will use the same devices, but they will not see the data in real time. Instead, they will manage their insulin based on standard finger-prick blood sugar checks four times a day, as typically done in standard care.\n\nBoth groups will be followed for 12 weeks after hospital discharge. Medical check-ins will occur in weeks 1, 2, 4, 8, and 12. Blood tests and treatment adjustments will be performed as needed.\n\nThe main goals are:\n\nTo measure if the use of technology helps patients stick to their insulin schedule (fewer missed or mistimed injections).\n\nTo see if it leads to better blood glucose control (e.g., more time within the recommended range, fewer episodes of low or high glucose).\n\nTo evaluate patient satisfaction with this technology and check if the number of unplanned hospital readmissions decreases.\n\nThe study will take place at Hospital Universitari i Politècnic La Fe in Valencia, Spain. Around 80 patients will participate.\n\nThis study is important because real-world data about the use of CGM and smart insulin devices during the hospital-to-home transition are limited. It may help improve diabetes care for people starting insulin after hospitalization.",[105,106,107,108,109],"Type 2 Diabetes Mellitus (T2DM)","Continuous Glucose Monitoring","CGM","Transition to Discharge","Smart Insulin Pen Cap",[111,112,113,114,115,116,117],"Type 2 Diabetes Mellitus","cgm","Continuous glucose monitoring","Transition to discharge","smart insulin pen cap","discharge","Insulinized patients","2026-01-22",{"date":120,"type":49},"2026-01-23",{"date":122,"type":49},"2024-08-01",{"date":124,"type":22},"2026-07",{"name":55,"class":56},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":133,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":57},"100590119","phase-3-validation-of-the-sentinel-lymph-node-technique-in-early-stage-ovarian-cancer-sentov-ii-100590119","NCT06963268","Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)","SENTOV II","Inclusion Criteria:\n\n* Signed informed consent prior to the performance of any procedure related to the clinical trial.\n* Female, 18 years of age or older at the time of inclusion.\n* Patients with a histopathological diagnosis of malignant ovarian tumor in a deferred study (any epithelial histology), in apparent early stage FIGO I-II, proposed for staging surgery, or patients with suspected malignant ovarian tumor in apparent early stage FIGO I-II, who will undergo exploratory laparotomy and operative biopsy, and if positive, will undergo staging surgery.\n\nExclusion Criteria:\n\n* Failure to obtain informed consent or revocation of informed consent.\n* Under 18 years of age at the time of inclusion.\n* Previous history of vascular surgery on the aorta, vena cava, or pelvic vessels.\n* Previous pelvic or paraaortic lymphatic surgery.\n* Previous lymphoma.\n* Previous abdomino-pelvic tumor.\n* Previous allergy to Tc99 or ICG.\n* Pregnancy\u002FBreastfeeding.\n\nPatients who have signed informed consent but do not meet all inclusion criteria and none of the exclusion criteria will be considered as selection failures.","FEMALE",{"count":135,"type":22},200,[137],"PHASE3","This clinical trial investigates the sentinel lymph node (SLN) technique as a less invasive alternative to conventional lymphadenectomy in patients with early-stage ovarian cancer. The primary objective is to evaluate the effectiveness, safety, and diagnostic accuracy of the SLN approach in detecting lymphatic metastases. By assessing its negative predictive value, the study aims to determine whether the SLN technique can reliably replace systematic pelvic and paraaortic lymphadenectomy. If successful, this technique could minimize surgical morbidity, shorten hospitalization stays, and lower complication rates, ultimately improving patient outcomes.",[140],"Ovarian Neoplasms",[142],"Sentinel Node Technique","2025-12-12",{"date":145,"type":49},"2025-12-19",{"date":147,"type":49},"2025-11-10",{"date":149,"type":22},"2028-06",{"name":55,"class":56},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":133,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":161,"studyType":70,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":175,"locationsCount":57},"100611286","impact-of-ufps-and-mnps-on-fetal-health-100611286","NCT07238608","Impact of UFPs and MNPs on Fetal Health","UPRISE Unravelling Ultrafine Particulate Matter and Micro Nano Plastic's Mechanisms of Impact on Fetal Health","UPRISE","Inclusion Criteria:\n\n* Agreement to sign the informed consent;\n* Non-smoking mothers and no exposure to environmental (second-hand) smoke (smoking influences UFP measurements);\n* ≥18 years old (mothers have to place sensors, mothers with childhood pregnancies may live at their parental home);\n* Not expecting to terminate the pregnancy (no measurements of the child);\n* Having resided in the geographical area of research for a minimum period of 1 year (to be eligible for modeling exposures).\n\nExclusion Criteria:\n\n* First visit after 11 weeks of gestation (to ensure 2-week monitoring in the first trimester);\n* Pregnancy complications that limit exposure measurements in urine (because it may cause polyuria, for example, gestational diabetes);\n* Known kidney disease (might influence exposure measurements in urine);\n* Multiple pregnancy (twin or more pregnancies may have a higher risk for complications or preterm birth, no measurements in the last trimester).",{"count":160,"type":22},1600,"5 Years","This project aims at unravelling mechanisms by which exposure to air pollution (in particular Ultrafine Particulate (UFP, PM0.1), and micro nano plastic's) interferes with the normal foetus development, with a short-term causal effect in higher likeliness of preterm delivery which, in consequence, precondition a higher likeliness to suffer non-communicable diseases (NCD) later in the life.",[164],"Pregnant Women",[166,167,168],"non-communicable diseases","Ultrafine Particulate","micro nano plastics","2025-11-15",{"date":171,"type":49},"2025-11-20",{"date":173,"type":22},"2026-01-01",{"date":89,"type":22},{"name":55,"class":56},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":57},"100595862","advancing-portable-brain-imaging-the-nextmri-projects-role-in-revolutionizing-diagnostic-mri-100595862","NCT07037966","Advancing Portable Brain Imaging: The NextMRI Project's Role in Revolutionizing Diagnostic MRI","Truly Portable MRI for Extremity and Brain Imaging Anywhere & Everywhere","Inclusion Criteria:\n\n* Patients with suspected multiple sclerosis\n\nExclusion Criteria:\n\n* Any contradictions for high-field MRI","65 Years",{"count":21,"type":22},[25],"Mobile imaging diagnostic devices are extremely valuable for clinical diagnosis both inside and outside healthcare facilities. However, Magnetic Resonance Imaging (MRI)-the gold standard for diagnosing many neurological and musculoskeletal conditions-is not easily portable. Moreover, due to its high cost (in the million-euro range) and limited availability, the average wait time in Europe for an MRI scan is from several weeks to months.\n\nThe NextMRI project aims to take the technical, industrial, and commercial steps required to deploy portable low-field MRI systems in remote and developing regions, rural areas, sporting events, military or medical camps, and home healthcare settings, improving diagnostic capabilities. The specific goals of the NextMRI project are:\n\n1. Expand current low-field MRI technology to brain imaging.\n2. Enhance diagnostic accuracy using machine learning.\n3. Improve portability and usability for end users.\n4. Reduce production costs for broader affordability.\n5. Collect clinical evidence through trials to validate medical performance.\n6. Develop a sustainable business model for market commercialization.",[188],"Multiple Sclerosis",[190,191,192],"multiple sclerosis","MRI","Brain Imaging","2025-09-22",{"date":195,"type":49},"2025-09-23",{"date":197,"type":22},"2025-10",{"date":199,"type":22},"2026-09",{"name":55,"class":56},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":217,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},"100587922","exercise-to-fight-obesity-100587922","NCT06934681","Exercise to Fight Obesity","Impact of a Structured Physical Exercise Program on Body Composition in Morbid Obesity: A Randomized Controlled Trial","ExFO","Inclusion Criteria:\n\n* Age: 18-65 years\n* BMI ≥35 with comorbidities, or ≥40, regardless of comorbidity presence\n\nExclusion Criteria:\n\n* Participation in a structured physical exercise program within the past 6 months\n* Presence of musculoskeletal or systemic diseases that prevent participation in a physical exercise program\n* Uncontrolled hypertension\n* Uncontrolled diabetes, particularly in the presence of severe complications (neuropathy and\u002For diabetic foot, proliferative retinopathy)\n* Uncontrolled or unstable cardiovascular disease (acute myocardial infarction within the past year, angina, heart failure, peripheral artery disease)",{"count":210,"type":22},72,[25],"This clinical trial aims to determinate whether a structured exercise program, supported by telerehabilitation, can help individuals with severe obesity who are going to undergo bariatric surgery.\n\nThe main objective of this study is whether a structured exercise program, including both supervised and home-based workouts, leads to greater body fat loss and improved strength compared to usual care. Furthermore, it also aims to evaluate other potentially affected aspects, such as body composition and functionality, quality of life, cardiovascular fitness, and various genetic and metabolic factors.\n\nThis study is a randomized clinical trial with two groups:\n\n* The intervention group will follow a structured exercise program both pre- and post- surgery.\n* The control group will receive standard care, including nutritional counseling and general health advice.\n\nThe study will include 72 adults with severe obesity (36 men and 36 women), all of whom will be randomly assigned to either the intervention or control group.\n\nParticipants in the exercise group will follow these steps:\n\n1. Before Surgery (Prehabilitation): A 26-week program with aerobic and strength exercises, done in-person or remotely 2-4 times per week.\n2. Pre-Surgery Maintenance: A flexible period before surgery where participants continue exercising on their own.\n3. After Surgery (Rehabilitation): A 20-week program focused on recovery and strength.\n4. Post-Surgery Maintenance: A long-term, self-guided phase to maintain progress.\n\nParticipants in the exercise group will also receive the same care as the control group, including nutrition counseling and medical checkups.\n\nTo evaluate participant progress, a series of measurements will be carried out, including:\n\n* BMI and body composition\n* Physical function assessed through isometric strength tests and other measures such as the Sit-to-Stand test and the 6-Minute Walk Test\n* Quality of life and lifestyle assessed using validated questionnaires\n* Daily physical activity measured with pedometers\n* Metabolic and genetic analysis from blood samples\n\nIf proven effective, this program could help establish structured exercise with telerehabilitation as a standard component of obesity care. The results may support the integration of exercise programs into clinical practice, leading to improved long-term outcomes for individuals with severe obesity undergoing bariatric surgery. Additionally, insights into genetic and metabolic factors may contribute to the development of personalized treatment strategies.",[214,215,216],"Morbid Obesity","Bariatric Surgery","Telerehabilitation",[218,219,216,220,221,222,223,224],"Bariatric surgery","Physical Exercise","Prehabilitation","Rehabilitation","Body composition","Morbid obesity","Functional capacity","2025-05-31",{"date":227,"type":49},"2025-06-04",{"date":229,"type":49},"2025-05-19",{"date":231,"type":22},"2029-04",{"name":55,"class":56},2,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":57},"100582704","efficacy-of-biomarkers-and-ceus-versus-cta-in-aaa-follow-up-post-evar-100582704","NCT06866769","Efficacy of Biomarkers and CEUS Versus CTA in AAA Follow-up Post-EVAR","Comparación De La Eficacia Entre Biomarcadores Y Ecografía Con Contraste Frente a Angio-TC En El Seguimiento De Aneurismas De Aorta Abdominal (AAA) Tras Reparación Endovascular (EVAR)","EVAR-markers","Inclusion Criteria:\n\n* patients with AAA under follow-up who are going to be treated with EVAR.\n* signed informed consent to perform CTA, CEUS and for the determination of biomarkers.\n\nExclusion Criteria:\n\n* patients with inflammatory abdominal aortic aneurysms or ruptured aneurysm.",{"count":243,"type":22},60,"This prospective observational study evaluates the efficacy of contrast-enhanced ultrasound and biomarker determination in the follow-up of patients with abdominal aortic aneurysm (AAA) treated with Endovascular Aneurysm Repair (EVAR). Currently, computed tomography angiography (CTA) is the standard for follow-up, although it has disadvantages such as radiation exposure and the use of iodinated contrasts. Contrast-enhanced ultrasound (CEUS), free of radiation and nephrotoxicity, and biomarkers could reduce the need for CTA minimizing the associated risks. Biomarkers will be measured before and after EVAR and CEUS will be performed at various time points and compared with CTA results to validate concordance and effectiveness in detecting endoleaks and aneurysm remodeling. The objectives include determining the efficacy of these combined methods and establishing a follow-up protocol that reduces exposure to radiation and iodinated contrast agents.",[246],"Abdominal Aortic Aneurysm Without Rupture",[248,249,250,251,252],"Abdominal Aortic Aneurysm (AAA)","Endovascular Aneurysm Repair (EVAR)","Contrast-enhanced ultrasound (CEUS)","Computed tomography angiography (CTA)","Biomarkers.","2025-03-05",{"date":255,"type":49},"2025-03-10",{"date":257,"type":49},"2024-07-25",{"date":259,"type":22},"2028-04-30",{"name":55,"class":56},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":57},"100520013","compative-study-of-pe-in-thrombosed-avf-after-balloon-thrombectomy-vs-thromboaspiration-100520013","NCT06051032","Compative Study of PE in Thrombosed AVF After Balloon Thrombectomy Vs. Thromboaspiration.","Prospective Randomized Comparative Study on the Incidence of Pulmonary Emboembolism (PE) After Endovascular Treatment of Thrombosed Dialysis Arterio Venous Fistulas (AVF): Balloon Thrombectomy Versus Thromboaspiration Systems.","Inclusion Criteria:\n\n* Patients with acute thrombosis (\\\u003C 10 days) of native or prosthetic AVF.\n\nExclusion Criteria:\n\n* Known pulmonary hypertension.\n* Severe pulmonary disease.\n* Low cardiopulmonary reserve.\n* Recent creation of vascular access.\n* Known right left shunt.\n* Access infection.\n* Allergy to iodinated contrast.\n* Patients under 18 years old.",{"count":243,"type":22},[25],"The goal of this multicentric clinical trial is to compare the incidence of pulmonary thromboembolism (PTE), assessed through AngioCT, in the endovascular treatment of acute thrombosis in native and prosthetic arteriovenous fistulas (AVF). The main questions it aims to answer are:\n\n* What is the difference in the incidence of pulmonary thromboembolism (PTE) assessed by AngioCT in endovascular treatment of acute thrombosis of native and prosthetic arteriovenous fistulas using balloon thrombectomy versus thromboaspiration systems?\n* What is the primary patency rate of arteriovenous fistulas treated with balloon thrombectomy versus thromboaspiration systems?\n* What is the clinical success rate in the treatment of arteriovenous fistulas using balloon thrombectomy compared to thromboaspiration systems?\n* What are the costs associated with the different thrombectomy techniques in the treatment of arteriovenous fistulas?\n\nParticipants will be underwent to balloon thrombectomy versus thromboaspiration systems.\n\nResearchers will compare the patients treated with balloon thrombectomy and thromboaspiration systems to see if the incidence of PE is comparable and to evaluate the primary and secondary patency rates of both thrombectomy techniques, the clinical technical success rate, and the costs associated with each technique.",[272],"Pulmonary Embolism and Thrombosis","2025-01-24",{"date":275,"type":49},"2025-01-28",{"date":277,"type":49},"2023-07-21",{"date":279,"type":22},"2025-03",{"name":55,"class":56},""]